Rather than relying on a single brightening hero, this affordable lotion stacks three regulated or well-studied actives — arbutin, tranexamic acid, and a stable vitamin C derivative — that target pigmentation through different pathways, all in a hydrating, fragrance-free base. Getting that combination as a Japanese quasi-drug at drugstore pricing is genuinely unusual.
A rare three-active brightening lotion at a drugstore price: arbutin, tranexamic acid, and a stable vitamin C derivative in a hydrating, fragrance-free base, all under Japanese quasi-drug regulation. Best for normal to dry skin chasing gradual fading of dark spots and dullness who will commit to daily sunscreen. Expect a slow burn, not a dramatic overnight change.
Promisingfor HyperpigmentationIn your profileYou chose · Tranexamic Acid has trial-level evidence for hyperpigmentation but no guideline or regulatory standing yet — promising, short of a recommendation; the other actives here are not yet assessed for it.Moderate evidenceGentleNo reviews collected yet
The case for it
Tranexamic Acid has trial-level evidence for this concern but no guideline or regulatory standing yet.
It is plausibly present at a working level, though the concentration is not declared.
The formula carries none of the triggers this concern is sensitive to.
What would change this: A declared concentration would move this to a firmer reading of the dose.
Same rule for everyone. “Promising” is the verdict on 7,858 of 45,024 concern verdicts across the catalog; rule R9p decided 7,858 of them.
Unchanged since September 5, 2026, engine 5.1.1.
R9p — 0.5.0: 'Unproven' beside three filled dots read as one question answered twice with opposite words (7,018 rows). The chip measures standing, the dots measure trial volume; where the row carries at least one RCT or a tier-2 source (moderate dots) and the active is present at a working level, the honest word is Promising. Unproven is reserved for plausible-standing rows with limited or weak evidence, or an under-dosed form. Same rank as Unproven — a bet either way; the dots order them. · the full register
Carrying active
Tranexamic Acid
Standing
plausible — trials support it
Form
plausible — studied range 2–5%, from the OTC monograph or label; needs leave-on contact; judge it after ~12 weeks
Tolerability
gentle
Row checked
against its sources on July 17, 2026 (evidence table ev-2026.09-r228)
Promisingfor Dark SpotsIn your profileYou chose · Vitamin C has trial-level evidence for dark spots but no guideline or regulatory standing yet — promising, short of a recommendation; the other actives here are not yet assessed for it.Moderate evidenceGentleNo reviews collected yet
The case for it
Magnesium Ascorbyl Phosphate has trial-level evidence for this concern but no guideline or regulatory standing yet.
It is plausibly present at a working level, though the concentration is not declared.
The formula carries none of the triggers this concern is sensitive to.
What would change this: A declared concentration would move this to a firmer reading of the dose.
Same rule for everyone. “Promising” is the verdict on 7,858 of 45,024 concern verdicts across the catalog; rule R9p decided 7,858 of them.
Unchanged since September 5, 2026, engine 5.1.1.
R9p — 0.5.0: 'Unproven' beside three filled dots read as one question answered twice with opposite words (7,018 rows). The chip measures standing, the dots measure trial volume; where the row carries at least one RCT or a tier-2 source (moderate dots) and the active is present at a working level, the honest word is Promising. Unproven is reserved for plausible-standing rows with limited or weak evidence, or an under-dosed form. Same rank as Unproven — a bet either way; the dots order them. · the full register
Carrying active
Magnesium Ascorbyl Phosphate
Standing
plausible — trials support it
Form
plausible — studied range 1–28%, from the trials on the row; needs leave-on contact; judge it after ~12 weeks
Tolerability
gentle
Row checked
against its sources on July 17, 2026 (evidence table ev-2026.09-r228)
Promisingfor DullnessIn your profileYou chose · Hyaluronic Acid has trial-level evidence for dullness but no guideline or regulatory standing yet — promising, short of a recommendation; the other actives here are not yet assessed for it.Moderate evidenceGentleNo reviews collected yet
The case for it
Two Types of Hyaluronic Acid has trial-level evidence for this concern but no guideline or regulatory standing yet.
It is plausibly present at a working level, though the concentration is not declared.
The formula carries none of the triggers this concern is sensitive to.
What would change this: A declared concentration would move this to a firmer reading of the dose.
Same rule for everyone. “Promising” is the verdict on 7,858 of 45,024 concern verdicts across the catalog; rule R9p decided 7,858 of them.
Unchanged since September 5, 2026, engine 5.1.1.
R9p — 0.5.0: 'Unproven' beside three filled dots read as one question answered twice with opposite words (7,018 rows). The chip measures standing, the dots measure trial volume; where the row carries at least one RCT or a tier-2 source (moderate dots) and the active is present at a working level, the honest word is Promising. Unproven is reserved for plausible-standing rows with limited or weak evidence, or an under-dosed form. Same rank as Unproven — a bet either way; the dots order them. · the full register
Carrying active
Two Types of Hyaluronic Acid
Standing
plausible — trials support it
Form
plausible
Tolerability
gentle
Row checked
against its sources on July 17, 2026 (evidence table ev-2026.09-r228)
Good choicefor MelasmaIn your profileYou chose · Tranexamic Acid is a trial-supported active for melasma; this liquid carries it, though the concentration is not declared.Strong evidenceGentleNo reviews collected yet
The case for it
Tranexamic Acid has trial-supported standing for this concern.
It is plausibly present at a working level, though the concentration is not declared.
The formula carries none of the triggers this concern is sensitive to.
What would change this: A declared concentration would move this to a firmer reading of the dose.
Same rule for everyone. “Good choice” is the verdict on 9,564 of 45,024 concern verdicts across the catalog; rule R5 decided 9,072 of them.
Unchanged since September 5, 2026, engine 5.1.1.
Promisingfor Sun DamageIn your profileYou chose · Vitamin C has trial-level evidence for sun damage but no guideline or regulatory standing yet — promising, short of a recommendation; the other actives here are not yet assessed for it.Moderate evidenceGentleNo reviews collected yet
The case for it
Magnesium Ascorbyl Phosphate has trial-level evidence for this concern but no guideline or regulatory standing yet.
It is plausibly present at a working level, though the concentration is not declared.
The formula carries none of the triggers this concern is sensitive to.
What would change this: A declared concentration would move this to a firmer reading of the dose.
Same rule for everyone. “Promising” is the verdict on 7,858 of 45,024 concern verdicts across the catalog; rule R9p decided 7,858 of them.
Unchanged since September 5, 2026, engine 5.1.1.
R9p — 0.5.0: 'Unproven' beside three filled dots read as one question answered twice with opposite words (7,018 rows). The chip measures standing, the dots measure trial volume; where the row carries at least one RCT or a tier-2 source (moderate dots) and the active is present at a working level, the honest word is Promising. Unproven is reserved for plausible-standing rows with limited or weak evidence, or an under-dosed form. Same rank as Unproven — a bet either way; the dots order them. · the full register
Carrying active
Magnesium Ascorbyl Phosphate
Standing
plausible — trials support it
Form
plausible
Tolerability
gentle
Row checked
against its sources on July 17, 2026 (evidence table ev-2026.09-r228)
The studies behind the evidence row
Use of topical ascorbic acid and its effects on photodamaged skin topography — Archives of Otolaryngology–Head & Neck Surgery — PubMed type includes 'Randomized Controlled Trial'; n=19 evaluable; active AND vehicle supplied by Cellex-C International; private facial plastic surgery practice (1999), opened July 16, 2026
Good choicefor DehydrationIn your profileYou chose · Hyaluronic Acid is a reference standard by mechanism for dehydration; this liquid carries it.Moderate evidenceGentleNo reviews collected yet
The case for it
Two Types of Hyaluronic Acid has trial-supported standing for this concern.
It is plausibly present at a working level, though the concentration is not declared.
The formula carries none of the triggers this concern is sensitive to.
What would change this: A declared concentration would move this to a firmer reading of the dose.
Same rule for everyone. “Good choice” is the verdict on 9,564 of 45,024 concern verdicts across the catalog; rule R5 decided 9,072 of them.
Unchanged since September 5, 2026, engine 5.1.1.
R5 — Trial-supported or guideline-supported active, adequately or plausibly dosed. · the full register
Carrying active
Two Types of Hyaluronic Acid
Standing
supported — its mechanism is established
Form
plausible — studied range 0.1%, from the trials on the row; needs leave-on contact; judge it after ~1 weeks
Tolerability
gentle
Row checked
against its sources on July 17, 2026 (evidence table ev-2026.09-r228)
The studies behind the evidence row
Draelos ZD, Cosmetic Dermatology: Products and Procedures — hyaluronic acid classified as a humectant water-binding agent holding many times its weight in water — reference work
Does the jobDoes what a toner is for: not alcohol-driven, adds something real. Not measured from the label: restores skin pH, plays well with what follows.
A verdict is DermApproved’s assessment of how well a product’s ingredients fit a concern — never a claim about what the product treats. Evidence dots and collected reviews sit beside it and are never blended in.
Rules 0.5.1 · evidence table ev-2026.09-r228 · how we decide
Assessment
Pros & Cons
Pros
✓ Three brightening actives — arbutin, tranexamic acid, vitamin C derivative
✓ Targets pigmentation through multiple complementary pathways
✓ Regulated Japanese quasi-drug, not just a marketing claim
✓ Hydrating, fragrance-free base that stays gentle
✓ Excellent value at around fourteen dollars for 170 mL
✓ Refill size available to lower long-term cost
✓ Soothing allantoin and squalane reduce active-related irritation
Cons
✗ Brightening is gradual and requires weeks of patience
✗ Contains methylparaben some users avoid
✗ Pregnancy safety uncertain due to the brightening actives
✗ Slightly higher irritation potential than a plain hydrator
✗ Wide-mouth bottle pours fast and wastes product
Review
Full Review
The word 'whitening' on a skincare label tends to make Western shoppers flinch, conjuring images of bleaching creams and uncomfortable beauty politics. It is worth clearing that up before anything else, because Hada Labo's Shirojyun Arbutin Whitening Lotion is not what that word implies. In Japanese skincare, 'whitening' is a regulated category that means brightening — fading sun spots, post-acne marks, and dullness back toward your skin's own even baseline. It does not lighten skin below its natural tone, and the actives that drive it are some of the best-studied pigmentation tools in dermatology. With that context in place, this lotion becomes a far more interesting product than its name suggests.
What makes it genuinely notable is that it is a 'medicated' lotion — in Japanese regulatory terms, a quasi-drug. That classification matters. It means the brightening actives are not just sprinkled in for the label; they are present at approved, regulated levels and the brightening claims have cleared Japanese authorities. The headline active is arbutin, a naturally derived tyrosinase inhibitor that slowly releases hydroquinone-like activity to suppress melanin formation. But the formula does not stop there. It layers in tranexamic acid, a second approved whitening active that works through an entirely different mechanism — interrupting the inflammatory crosstalk between skin cells and pigment-producing melanocytes, which makes it particularly effective for melasma and post-inflammatory marks. And it adds magnesium ascorbyl phosphate, a stable, gentle vitamin C derivative that contributes antioxidant defense and a mild brightening assist. Three actives, three pathways, attacking pigmentation from multiple directions at once. Finding that combination in a quasi-drug lotion at drugstore pricing is, frankly, a small feat of value engineering.
Crucially, the brand has not let the active load turn this into a harsh, drying product. The base is recognizably Hada Labo: two forms of hyaluronic acid, glycerin, and a clutch of humectants keep the skin hydrated and comfortable, so the brightening agents land on a well-moisturized canvas rather than a tight, dehydrated one. Allantoin and a touch of squalane add soothing and emollient support, and coix seed (hatomugi) extract, a traditional Japanese skin ingredient, rounds things out. The result is a lotion that feels like a hydrating toner with benefits, not a stinging treatment you have to brace for.
In use, it is a watery, faintly viscous liquid with a light slip that absorbs in seconds to a soft, non-sticky finish. The application ritual is the familiar Japanese one: a few drops pressed into damp skin after cleansing, layered two or three times if you want more, before serums and moisturizer. There is no fragrance beyond a faint neutral base note, and for most people no sensation at all — though a small minority of reactive users report a brief, mild sting from the actives, so a patch test is sensible if your skin is temperamental. There is no purging and no dramatic first impression; the brightening is a slow, quiet build.
And that patience is the thing to be honest about. This is not a product that transforms your face in a week. Hydration and a smoother feel are immediate, but tone improvement realistically takes around a month to begin showing, and established dark spots need eight to twelve weeks of consistent daily use to visibly fade. That is not a knock on the formula — it is simply how brightening actives work, and any product promising faster is overselling. The non-negotiable companion to all of this is sunscreen. Inhibiting melanin production while letting UV light stimulate fresh pigment is a self-defeating exercise; without diligent daily SPF, you undercut the entire point of the lotion. If you are not willing to wear sunscreen every day, this product is not worth buying.
The limitations beyond patience are modest. The active stack, gentle as it is, carries a slightly higher irritation potential than a plain hydrator, which is reflected in its scoring. The formula uses methylparaben — well-studied and safe at these levels, but a dealbreaker for anyone who specifically avoids parabens. The wide-mouth bottle pours fast and wastes product if you are not careful, the same minor gripe that haunts the whole brand. And while it is hydrating, it is a lotion, not a moisturizer, so it needs a cream sealed over it. Pregnancy safety is genuinely uncertain here — tranexamic acid and arbutin are not clearly established as safe in topical pregnancy use, so anyone pregnant or nursing should check with their doctor rather than assume.
On value, there is very little to complain about. Around fourteen dollars buys 170 millilitres of a triple-active, regulated brightening lotion, with a 400 millilitre refill available to push the cost lower for long-term users. You are not paying for a luxury serum's marketing; you are paying for a competent, ingredient-forward formula from a brand that has refined this exact category for two decades. Compared to the price of dedicated arbutin or tranexamic acid serums, getting all three actives plus solid hydration at this price is a standout.
The verdict is straightforward. If you have normal, combination, or dry skin, you are dealing with sun spots, post-acne marks, or general dullness, and you are genuinely committed to daily sunscreen and a patient timeline, this lotion is one of the smartest brightening buys at the drugstore level. If you want overnight results, refuse to wear SPF, avoid parabens, or have very reactive skin that flares at the mildest active, look elsewhere. For the patient and the practical, though, it quietly over-delivers on its modest price.
Formula
Key Ingredients
The hero actives that drive this product's performance.
The lead brightening active in this 'medicated' lotion, a regulated tyrosinase inhibitor that slowly releases hydroquinone-like activity to curb melanin production. Paired here with tranexamic acid and a stable vitamin C derivative, it targets dark spots from a different angle than either alone.
A second approved whitening active that interrupts the inflammatory signaling between keratinocytes and melanocytes — especially useful for post-inflammatory marks and melasma. In this formula it complements arbutin's tyrosinase inhibition, attacking pigmentation through a parallel pathway.
A stable, water-soluble vitamin C derivative that adds antioxidant support and a mild brightening assist. Less irritating than pure ascorbic acid, it suits this gentle daily lotion and rounds out the three-active brightening approach without raising the irritation profile.
Standard and hydrolyzed nano hyaluronic acid keep the lotion comfortably hydrating despite its active load, ensuring the brightening agents are delivered on a well-moisturized canvas rather than a tight, dehydrated one that would amplify irritation.
Established mechanismfor Dehydration · established mechanism
Ingredient standings describe the active at treatment-level doses and
vehicles; this product's own condition grades weigh its actual formula.
Pat a few drops into clean, damp skin before serums and moisturizer. Because it carries brightening actives, daytime use must be paired with diligent sunscreen — without SPF, you undercut the entire point of fading pigmentation.
Results Timeline
Hydration and a smoother feel are immediate. Brightening is a slow burn — early tone improvement around the four-week mark, with visible fading of established dark spots typically needing eight to twelve weeks of consistent daily use plus sun protection.
Pairs Well With
Daily sunscreen (essential)Niacinamide serumsVitamin C serumsCeramide moisturizers
The brightening case here rests on three actives with substantial dermatological literature working through distinct mechanisms. Arbutin is a glycosylated derivative of hydroquinone that competitively inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis; studies report measurable reductions in melanin and hyperpigmentation with topical use, with a gentler profile than pure hydroquinone because the active is released gradually. Tranexamic acid addresses pigmentation through a separate route, interfering with the plasmin-driven signaling between keratinocytes and melanocytes and reducing melanocyte activation triggered by UV and inflammation; clinical research, particularly in melasma, supports topical tranexamic acid for evening tone. Magnesium ascorbyl phosphate is a stable vitamin C derivative that provides antioxidant protection and contributes mild brightening by interrupting oxidative steps in melanin formation, while being far less irritating and more shelf-stable than L-ascorbic acid. The strategic logic of combining them is multi-pathway inhibition — tyrosinase suppression, melanocyte-signaling interruption, and antioxidant support — which is generally more effective and better tolerated than maximizing a single aggressive agent. The hyaluronic acid and glycerin base is not incidental: maintaining hydration reduces the irritation that can paradoxically worsen pigmentation. The essential scientific caveat is that none of these actives works against ongoing UV exposure, so the entire approach depends on consistent photoprotection, and results accrue over weeks to months rather than days.
References
Tranexamic acid in the treatment of melasma: A review of the literature — American Journal of Clinical Dermatology (2019)
The safety and efficacy of arbutin in the treatment of hyperpigmentation — Journal of Cosmetic Dermatology (2022)
Dermatologist Perspective
Topical brightening agents like arbutin and tranexamic acid are frequently incorporated into clinical regimens for hyperpigmentation, sun-induced dark spots, and melasma, often valued because they offer melanin control through different mechanisms than hydroquinone. In clinical practice, combination approaches that pair a tyrosinase inhibitor with tranexamic acid and an antioxidant are commonly favored over a single high-strength agent, since multi-pathway suppression tends to be both more effective and better tolerated. Standard guidance emphasizes that any brightening protocol is only as good as the photoprotection accompanying it, and patients are routinely told that daily broad-spectrum sunscreen is mandatory rather than optional. Because pigmentation responds slowly, realistic timelines of two to three months are typically set. For patients who are pregnant or breastfeeding, clinicians generally advise caution with tranexamic acid and arbutin until cleared individually.
Guidance
Usage & Recommendations
How to Use
Right after cleansing, with skin still slightly moist, dispense a few drops and press the lotion into the face using your palms rather than rubbing, layering two or three passes if you want more hydration. Use it morning and night before serums and moisturizer. In the daytime, always follow your routine with a broad-spectrum sunscreen — this is essential, not optional, with any brightening product. Give the actives eight to twelve weeks of consistent use to show meaningful results on dark spots, and patch test first if your skin is reactive.
Value Assessment
At around fourteen dollars for 170 millilitres, this lotion is a standout on price-to-quality, delivering three brightening actives that often command serum-level pricing individually. A 400 millilitre refill format lowers the per-use cost further for committed users, and a few drops per application means a single bottle lasts two to three months. The value is amplified by the quasi-drug status: you are getting regulated, dose-vetted actives rather than token amounts in a cosmetic toner. The price reflects genuine formulation substance from a two-decade hydration specialist, not brand hype. For anyone building a budget pigmentation routine, getting arbutin, tranexamic acid, and a vitamin C derivative together at this cost is hard to beat.
Who Should Buy
This is ideal for normal, combination, or dry skin dealing with sun spots, post-acne marks, melasma, or general dullness who wants a hydrating, affordable brightening step and will commit to daily sunscreen. It suits budget-minded routine-builders who want multiple proven actives in one product rather than buying separate brightening serums.
Who Should Skip
Those expecting fast, dramatic lightening should look elsewhere — this is a slow, gradual brightener. Anyone unwilling to wear daily sunscreen will waste the actives entirely, and those who avoid parabens or have very reactive skin should pass or patch test carefully. Pregnant or nursing users should consult a doctor before use given the uncertain safety of the brightening actives.
Ready to try Hada Labo Shirojyun Arbutin Whitening Lotion?
A watery, faintly viscous lotion with a light slip that absorbs quickly. Marginally richer than a plain toner but still firmly in liquid-lotion territory, leaving a soft, non-sticky finish.
Scent
Fragrance-free, with only a faint neutral base note that dissipates on application.
Packaging
Tall blue plastic bottle with a wide pour opening and no pump — controlled dispensing takes a little practice. A 400 mL refill is available.
Finish
lightweightfast-absorbingnatural
What to Expect on First Use
Absorbs cleanly with a hydrated finish and usually no sensation, though a small number of reactive users notice a brief mild sting from the actives. No purging; brightening builds quietly over weeks rather than producing an immediate change.
How Long It Lasts
About 2 to 3 months with twice-daily layered use of a few drops per application.
Shirojyun ('shiro' meaning white) is Hada Labo's brightening counterpart to the hydration-focused Gokujyun line, built around Japan's strong cultural interest in even, luminous skin tone. The Arbutin lotion sits in the medicated tier, where actives must clear Japanese quasi-drug regulation, distinguishing it from purely cosmetic brightening toners.
About Hada Labo Established Brand (5–20 years)
Hada Labo, launched in 2004 by Japanese pharmaceutical company Rohto Mentholatum, is Japan's best-selling lotion brand. The Shirojyun line is a 'medicated' (quasi-drug) range, meaning its brightening actives arbutin and tranexamic acid are approved and dose-regulated by Japanese authorities — a real regulatory backing rather than a pure marketing claim.
Brand founded: 2004 · Product launched: 2013
Myth vs. Reality
Common Myths
Myth
A whitening lotion will bleach or lighten your natural skin color.
Reality
Despite the name, 'whitening' in Japanese skincare means brightening and evening tone — fading dark spots and dullness back toward your baseline. Arbutin and tranexamic acid reduce excess melanin from sun and inflammation; they don't lighten skin below its natural shade.
Myth
Brightening products work without sunscreen.
Reality
They actively don't. Inhibiting melanin while letting UV stimulate fresh pigment is a wash — daily sunscreen is non-negotiable with this lotion, and skipping it can leave you no better off or worse.
FAQ
Frequently Asked Questions
Does the Shirojyun Arbutin lotion actually whiten or bleach skin?
No. 'Whitening' here means brightening — fading dark spots, sun marks, and dullness toward your natural even tone. Its arbutin and tranexamic acid reduce excess melanin from sun and inflammation; they do not lighten skin below its baseline shade.
What brightening actives are in the Hada Labo Shirojyun Arbutin Lotion?
It combines three: arbutin (a tyrosinase-inhibiting whitening agent), tranexamic acid (which interrupts melanocyte-activating inflammation), and magnesium ascorbyl phosphate, a stable vitamin C derivative. Together they target pigmentation through complementary pathways.
How long does the Hada Labo Shirojyun lotion take to fade dark spots?
Hydration is immediate, but brightening is gradual. Tone improvement typically begins around four weeks, with visible fading of established dark spots usually needing eight to twelve weeks of consistent daily use paired with sunscreen.
Do I need sunscreen with the Shirojyun Arbutin Whitening Lotion?
Absolutely. Sunscreen is mandatory with this lotion — UV exposure stimulates the very pigment the actives are trying to reduce. Without daily broad-spectrum SPF, you cancel out the brightening effort and may see no improvement at all.
Is the Hada Labo Shirojyun Arbutin Lotion safe during pregnancy?
Its safety in pregnancy is uncertain. Tranexamic acid and arbutin are not clearly established as safe for topical use while pregnant or nursing, so anyone in that situation should consult a doctor before using it rather than assume it is fine.
Is the Shirojyun Arbutin lotion gentle enough for daily use?
For most people, yes — the hydrating, fragrance-free base with allantoin and squalane keeps it comfortable for twice-daily use. A small number of reactive users feel a brief mild sting from the actives, so patch testing is wise for sensitive skin.
Reviews
What Reviewers Tend to Say
Recurring themes our editors read across retailer reviews of this product — summaries in our words, not quotations, and not a substitute for your own patch test.
Common Praise
Affordable multi-active brightening lotion
Hydrating despite the actives
Gentle enough for daily use
Helps even out dull tone over time
Common Complaints
Brightening is gradual, not dramatic
Contains methylparaben
Wide-mouth bottle pours fast
A few sensitive users find it slightly stingy
Notable Endorsements
Long-running brightening staple in Japanese drugstore skincareFrequently discussed in J-beauty pigmentation routines
Japan runs a third regulatory tier between cosmetic and pharmaceutical, and once you can see it, the entire J-beauty aisle stops looking modest and starts looking legally precise.
Most heritage claims are unfalsifiable. This one sits on a public regulatory register — which makes it the rare case where you can check what 150 years of institutional research actually bought.
The one home formulation with a genuinely coherent case, taken apart on its own terms: the pH window, the oxidation clock, and what a browning serum has actually become.
It was invented to stop bleeding during surgery. In 2026 it's in dozens of brightening serums — and the evidence is better than most trend ingredients can claim.
Jul 6, 2026· 3 min
Questions people ask about Hyperpigmentation
Verified answers from our questions library — the nuance a product page cannot carry.
Products, answers, therapy guides, tools and articles in one search. Brand names,
slang and abbreviations all work — accutane finds isotretinoin, bacne finds truncal acne.